<DOC>
	<DOCNO>NCT00085254</DOCNO>
	<brief_summary>Cilengitide may stop growth cancer stop blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-rays damage tumor cell . Giving cilengitide together temozolomide radiation therapy may kill tumor cell . This randomized phase I/II trial study side effect best dose cilengitide give together temozolomide radiation therapy compare well work treat patient newly diagnose glioblastoma multiforme</brief_summary>
	<brief_title>Cilengitide , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety profile EMD 121974 ( cilengitide ) administer one-hour infusion twice week concurrently concomitant adjuvant temozolomide radiation therapy newly diagnose glioblastoma multiforme . ( Safety Run-In ) II . To estimate overall survival newly diagnose patient glioblastoma multiforme treat EMD 121974 concurrently concomitant adjuvant temozolomide radiation therapy . ( Phase II ) SECONDARY OBJECTIVES : I . To estimate compare overall survival low dose treatment group high dose treatment group newly diagnose patient glioblastoma multiforme treat EMD 121974 concurrently concomitant adjuvant temozolomide radiation therapy . ( Phase II ) II . To determine toxicity EMD 121974 ( cilengitide ) administer conjunction concomitant adjuvant temozolomide radiation therapy patient newly diagnose glioblastoma multiforme . ( Phase II ) III . To evaluate molecular profile individual patient correlate molecular expression profile clinical outcome . ( Phase II ) IV . To characterize tumor blood volume , tumor blood flow , permeability ratio use perfusion MR newly diagnose glioblastoma multiforme follow parameter treatment EMD 121974 ( cilengitide ) . ( Phase II ) OUTLINE : This open-label , multicenter , safety run-in study cilengitide follow randomized phase II study . Safety Run-In : INITIATION COURSE : Patients receive cilengitide IV 1 hour day 1 4 . Treatment repeat weekly 10 week . Patients also receive oral temozolomide undergo radiotherapy one hour late day 1-5 week 1-6 . MAINTENANCE COURSES : Patients receive oral temozolomide daily day 1-5 course 1-6 . Patients also receive cilengitide IV day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos cilengitide ( 3 Pre-defined study dose level define : 500 , 1000 2000mg ) . The MTD define dose precede 2 3 3 6 patient experience dose-limiting toxicity . If MTD ( maximum tolerable dose ) define three step dose escalation process , pursue phase II safety/efficacy study randomize treatment allocation . Patients randomize one two pre-specified treatment dosage arm , 500mg group 2000mg group . PHASE II : Patients stratify accord age ( 50 vs 50 ) , Karnofsky performance score ( 60 % -80 % v 90 % -100 % ) , tumor status ( measurable v nonmeasurable ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive radiotherapy temozolomide safety run-in initiation course cilengitide low dose safety run-in initiation maintenance course . ARM II : Patients receive radiotherapy temozolomide safety run-in initiation course cilengitide high dose safety run-in initiation maintenance course . Patients follow every 2 month . PROJECTED ACCRUAL : A total 9-112 patient ( 9-18 safety run-in 94 [ 47 per treatment arm ] phase II ) accrue study within 1.5-37 month</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must histologically confirm supratentorial grade IV astrocytoma ( glioblastoma multiforme ) Patients must receive prior radiation therapy , chemotherapy , immunotherapy therapy biologic agent ( include immunotoxins , immunoconjugates , antisense , peptide receptor antagonist , interferon , interleukin , TIL , LAK gene therapy ) , hormonal therapy brain tumor ; glucocorticoid therapy allow Patients must Karnofsky performance status &gt; = 60 % ( i.e . patient must able care himself/herself occasional help others ) Absolute neutrophil count &gt; = 1500/mm^3 Platelets &gt; = 100,000/mm^3 Creatinine = &lt; 1.5 mg/dl creatinine clearance &gt; = 60 mL/min Total bilirubin = &lt; 1.5 mg/dl Transaminases = &lt; 4 time upper limit institutional normal Patients must able provide write informed consent Patients must recover immediate postoperative period maintain stable corticosteroid regimen ( increase 5 day ) prior start treatment Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception ; woman childbearing potential must negative pregnancy test Patients must Mini Mental State Exam score &gt; = 15 Patients must tumor tissue form complete signed pathologist Patients serious concurrent infection medical illness , would jeopardize ability patient receive treatment outline protocol reasonable safety Patients pregnant breastfeeding Patients receive concurrent therapy tumor ( i.e . chemotherapeutics investigational agent ) Patients concurrent prior malignancy ineligible unless patient curatively treat carcinomainsitu basal cell carcinoma skin ; patient free disease ( prior malignancy ) &gt; = five year eligible study Patients unable undergo MRI evaluation Patients history woundhealing disorder , advance coronary disease , recent history ( # 1 year ) peptic ulcer disease ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>